An automated causality assessment algorithm to detect drug-induced liver injury in electronic medical record data

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 6, 2014, Pages 601-608

  Cheetham, T Craig ^a   Lee, Janet ^a   Hunt, Christine M ^b,c   Niu, Fang ^a   Reisinger, Steph ^d   Murray, Rich ^d   Powell, Greg ^b   Papay, Julie ^b  

^a KAISER PERMANENTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Algorithm; Automated; Causality assessment; Drug safety; Drug induced; Liver injury; Pharmacoepidemiology; Risk assessment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ARIPIPRAZOLE; BETA INTERFERON; CIPROFLOXACIN; COTRIMOXAZOLE; DICLOFENAC; DULOXETINE; ISONIAZID; LAMOTRIGINE; LEVOFLOXACIN; NITROFURANTOIN; PHENYTOIN; TERBINAFINE; VALPROIC ACID; PRESCRIPTION DRUG;

ALCOHOL CONSUMPTION; ARTICLE; CLASSIFICATION ALGORITHM; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PREGNANCY; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD; TOXIC HEPATITIS; WILCOXON SIGNED RANKS TEST; ALGORITHM; DRUG-INDUCED LIVER INJURY; FACTUAL DATABASE; PILOT STUDY; STANDARDS;

ALGORITHMS; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; ELECTRONIC HEALTH RECORDS; HUMANS; PILOT PROJECTS; PRESCRIPTION DRUGS;

EID: 84901824190     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3531     Document Type: Article

References (24)

1. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
2. Bleibel W, Kim S, D'Silva K, et al. Drug-induced liver injury: review article. Dig Dis Sci 2007; 52: 2463-2471.
3. Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-522.
4. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-2076.
5. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999; 319: 1541.
6. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
7. Andrade RJ, Camargo Raquel, Lucena MI, et al. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004; 3: 329-344.
8. Miljkovic MM, Dobric S, Dragojevic-Simic V. Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. Pharmacoepidemiol Drug Saf 2011; 20: 272-285.
9. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatol. 2010; 51: 2117-2126.
10. Rochon J, Protiva P, Seef LB, et al. Reliability of the Roussel Uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatol. 2008; 48: 1175-1183.
11. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-815.
12. Shin J, Hunt CM, Suzuki A, et al. Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. Pharmacoepi Drug Safety. 2013; 22: 190-198.
13. Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012; 19: 54-60.
14. Nathwani RA, Pais S, Reynolds TB, et al. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005; 41: 380-382.
15. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123: 1367-1384.
16. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48: 1680-1689.
17. Spanish DILI Registry. http://www.spanishdili.uma.es/index.php?option=com_content&view=article&id=92&Itemid=83&lang=en [13 December 2012]
18. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. The Am Statistician. 1999; 53: 177-201.
19. Koebnick C, Langer-Gould R, Gould M, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US census bureau data. Perm J. 2012; 16: 37-41.
20. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934, 1934 e1-4.
21. FDA. New Molecular Entity Postmarketing Safety Evaluation Pilot Program Final Report. Volume 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm185252.htm#Results [December 2012]
22. Garcia-Cortez M, Stephens C, Lucena MI, et al. Causality assessment methods in drug-induced liver injury: strengths and weaknesses. J Hepatology 2011; 55: 683-691. http://jamia.bmj.com/content/early/2013/07/08/amiajnl-2013-001930.abstract. [10 September 2013]
23. Overby CL, Pathak J, Gottesman O, et al. A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury.
24. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepi Drug Safety 2012; 21(S1): 1-8.